The potential of mesenchymal stromal cells in neuroblastoma therapy for delivery of anti-cancer agents and hematopoietic recovery

Caroline Hochheuser, Nina Y. Kunze, Godelieve A.M. Tytgat, Carlijn Voermans, Ilse Timmerman

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

2 Citaten (Scopus)

Samenvatting

Neuroblastoma is one of the most common pediatric cancers and a major cause of cancerrelated death in infancy. Conventional therapies including high-dose chemotherapy, stem cell transplantation, and immunotherapy approach a limit in the treatment of high-risk neuroblastoma and prevention of relapse. In the last two decades, research unraveled a potential use of mesenchymal stromal cells in tumor therapy, as tumor-selective delivery vehicles for therapeutic compounds and oncolytic viruses and by means of supporting hematopoietic stem cell transplantation. Based on pre-clinical and clinical advances in neuroblastoma and other malignancies, we assess both the strong potential and the associated risks of using mesenchymal stromal cells in the therapy for neuroblastoma. Furthermore, we examine feasibility and safety aspects and discuss future directions for harnessing the advantageous properties of mesenchymal stromal cells for the advancement of therapy success.

Originele taal-2Engels
Artikelnummer161
Pagina's (van-tot)1-24
Aantal pagina's24
TijdschriftJournal of Personalized Medicine
Volume11
Nummer van het tijdschrift3
DOI's
StatusGepubliceerd - mrt. 2021

Vingerafdruk

Duik in de onderzoeksthema's van 'The potential of mesenchymal stromal cells in neuroblastoma therapy for delivery of anti-cancer agents and hematopoietic recovery'. Samen vormen ze een unieke vingerafdruk.

Citeer dit